Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-…

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting
β 2 -agonist (LABA) therapy in patients with chronic obstructive pulmonary …

Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease
Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with …

Background The safe and appropriate use of long-acting beta-agonists (LABAs) for the
treatment of asthma has been widely debated. In two large clinical trials, investigators found a …

Background Long-acting beta-agonists (LABAs) have been shown to increase the risk of
asthma-related death among adults and the risk of asthma-related hospitalization among …

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …

Background Patients with chronic obstructive pulmonary disease (COPD) have excess risk
of developing pneumonia; however, no definitive biomarkers of risk have been established. …

Hypoxia is common in many chronic lung diseases. Beyond pulmonary considerations, delivery
of oxygen (O 2 ) to the tissues and subsequent O 2 utilisation is also determined by other …

Background The Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease
(E-RS:COPD) is a patient-reported diary that assesses respiratory symptoms in stable …

Background There is no consensus on how to define patients with symptoms of asthma and
chronic obstructive pulmonary disease (COPD). A diagnosis of asthma–COPD overlap (ACO…